Author

Meagan Odegaard

Institutions: University of Central Florida, National Institutes of Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, National Cancer Institute, Center for Cancer Research, Sidney Kimmel Comprehensive Cancer Center

Observed institutions: University of Central Florida, National Institutes of Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, National Cancer Institute, Center for Cancer Research, Sidney Kimmel Comprehensive Cancer Center

OpenAlex ID: A5032652715

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

2024 · Andrea B. Apolo, Karla V. Ballman, et al. · New England Journal of Medicine · 170

Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.

2019 · Andrea B. Apolo, Jonathan E. Rosenberg, et al. · Journal of Clinical Oncology · 20

Works count: 2

Citation count: 188

H-index: 2

I10-index: 2